Aug 06, 2019
Cellular Biomedicine Group Reports Second Quarter and First Half of 2019 Financial Results and Business Highlights
Jul 23, 2019
Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019
Jun 17, 2019
Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China
May 29, 2019
Cellular Biomedicine Group to Present at International Society for Cell and Gene Therapy Annual Meeting
May 20, 2019
Cellular Biomedicine Group to Present at B. Riley FBR Annual Investor Conference
Apr 30, 2019
Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress
Apr 29, 2019
Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders
Apr 25, 2019
Cellular Biomedicine Group to Report First Quarter 2019 Results and Host Conference Call on May 1, 2019
Apr 23, 2019
Cellular Biomedicine Group Upgraded to NASDAQ Global Select Market
Apr 15, 2019
Cellular Biomedicine Group to Participate in Asia Pharma R&D Leaders Summit 2019
Apr 05, 2019
Cellular Biomedicine Group to Present at Annual BioCentury Future Leaders in the Biotech Industry Conference
Mar 20, 2019
Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock
Feb 27, 2019
Cellular Biomedicine Group to Present at 8th Annual SVB Leerink Global Healthcare Conference
Jan 17, 2019
Cellular Biomedicine Group's AlloJoin® Therapy for Knee Osteoarthritis (KOA) Becomes the First Stem Cell Drug Application Approved in China for Phase II Clinical Trials
Jan 08, 2019
Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)